This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

NCT06074497 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: KGX101- Cohort -1
DRUG: KGX101- Cohort 1
DRUG: KGX101- Cohort 2
DRUG: KGX101- Cohort 3
DRUG: KGX101- Cohort 4
DRUG: KGX101- Cohort 5
DRUG: KGX101 and Envafolimab

Sponsor

Kangabio AUSTRALIA LTD PTY